Hyperfine Announces Ten Abstracts at RSNA, Highlighting the Expanding Utility and Potential of Portable MR Brain Imaging in Diverse Clinical and Research Settings

HYPR 11.19.2024

Full Press ReleaseSEC FilingsOur HYPR Tweets

About Gravity Analytica

Recent News

  • 12.17.2024 - Hyperfine Expands Global Market Reach with New Distribution Partnerships in European and Middle Eastern Markets
  • 12.05.2024 - Hyperfine Announces Extensive Clinical Study Coverage at RSNA 2024, Showcasing the Body of Evidence Supporting the Use of the Swoop® System Across Different Sites of Care
  • 12.03.2024 - Hyperfine Announces Strategic Leadership Additions to Drive Growth in Key Business Verticals

Recent Filings

  • 11.18.2024 - 4 Statement of changes in beneficial ownership of securities

The breadth of data being presented at the premier radiology meeting of 2024 illustrates the increasing relevance of portable, ultra-low-field MR brain imaging.

GUILFORD, Conn.--(BUSINESS WIRE)--Nov. 19, 2024--Hyperfine, Inc.(Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that ten scientific abstracts highlighting ultra-low-field imaging will be presented at theRadiological Society of North America(RSNA) 2024 Annual Meeting inChicago. For Hyperfine, this marks the largest number of presentations at RSNA to date, underscoring the growing interest in and expanding applications of the Swoop® system across varied professional healthcare environments.

This press release features multimedia. View the full release here:https://www.businesswire.com/news/home/20241119768356/en/

The Swoop® Portable MR Imaging® System (Photo: Business Wire)

The Swoop® Portable MR Imaging® System (Photo: Business Wire)

“We’re excited by the scientific community’s remarkable enthusiasm for the Swoop® system,” said Dr.Edmond Knopp, Hyperfine Chief Medical Officer. “Watching our technology propel real-world applications across such diverse settings is a significant milestone for Hyperfine. We look forward to continued momentum with clinical evidence on the use of portable brain MRI and how it can transform brain imaging and enhance patient care.”

The ten abstracts highlight a broad range of clinical and technical applications across multiple sites of care, showcasing the Swoop® system’s versatility in supporting patient management. Clinical research to be presented spans workflow in both the emergency department and neuro ICU and covers clinician experience in intracerebral hemorrhage monitoring, acute ischemic stroke detection, and advanced imaging techniques for multiple sclerosis.

For more information about the Swoop® Portable MR Imaging® system, please visithyperfine.io.

Conference attendees can learn more during the presentations listed below.

Name:Acute stroke detection using portable ultra low-field MRI: A multicenter outlookPresented by:Nandor Kolos Pinter, MDSession:Neuroradiology (Stroke: Diagnosis and Treatment) | M3-SSNR04Date and time:Monday, December 2, 9:30–10:30 AMLocation:S406B

Name:Low-field (64mT) portable brain MRI in hospitalized and emergency department patients: Real-world experience from our first two yearsPresented by:Vinu Mathew, MDSession:Science Session (Low-Field and Mobile MRI) | T2-STCE1Date and time:Tuesday, December 3, 9:00–9:30 AMLocation:Learning Center Theater 1

Name:Application of clinical low field mobile MRI in a large academic medical centerPresented by:Farzaneh Rahmani, MD, MPHSession:Science Session (Low-Field and Mobile MRI) | R2-STCE1Date and time:Thursday, December 5, 9:00–9:30 AMLocation:Learning Center Theater 1

Name:Utility of low-field portable brain MRI for ruling out space-occupying lesions and hydrocephalus in patients with papilledema and other ophthalmologic signs of possible increased intracranial pressure: Preliminary experiencePresented by:Timothy Reynold Uy Lim, MDSession:Science Session (Low-Field and Mobile MRI) | M3-STCE2Date and time:Monday, December 2, 10:00–10:30 AMLocation:Learning Center Theater 2

Name:Efficacy of follow-up portable MRI compared to standard follow-up head CT for interval evaluation of traumatic intracranial hemorrhagePresented by:Lauren ThompsonSession:Science Session (Low-Field and Mobile MRI) | T6-STCE2Date and time:Tuesday, December 3, 1:30–2:00 PMLocation:Learning Center Theater 2

Name:A deep learning framework for generating synthetic low-field imaging with paired high and low-field dataPresented by:Alfredo Lucas, MS, BSSession:Science Session (Low-Field and Mobile MRI) | R2-STCE1Date and time:Thursday, December 5, 9:00–9:30 AMLocation:Learning Center Theater 1

Name:Quantifying brain volumes and lesion burden in relation to disease duration and severity in multiple sclerosis with low-field MRIPresented by:Alfredo Lucas, MS, BSSession:Science Session (Low-Field and Mobile MRI) | S1-STCE1Date and time:Sunday, December 1, 9:30–10:00 AMLocation:Learning Center Theater 1

Name:Detecting myelin loss at 0.064T using a novel myelin water imaging technique: A multiple sclerosis case studyPresented by:Shannon H. Kolind, PhDSession:Science Session (Low-Field and Mobile MRI) | M7-STCE1Date and time:Monday, December 2, 2:30–3:00 PMLocation:Learning Center Theater 1

Name:Implementation and reproducibility assessment of myelin-sensitive scans with mobile ultra-low field MRIPresented by:Sharada BalajiSession:Science Session (Low-Field and Mobile MRI) | R2-STCE1Date and time:Thursday, December 5, 9:00–9:30 AMLocation:Learning Center Theater 1

Name:Initial experience with low-field point-of-care MRI in animal stroke modelsPresented by:Nandor Kolos Pinter, MDSession:Neuroradiology Wednesday Afternoon Poster Discussions I | W5A-SPNRDate and time:Wednesday, December 4, 12:15–12:45 PMLocation:Learning Center (Poster Session)

About the Swoop® Portable MR Imaging® System

The Swoop® Portable MR Imaging® system isU.S. Food and Drug Administration(FDA) cleared for brain imaging of patients of all ages. It is a portable, ultra-low-field magnetic resonance imaging device for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop® system also has CE certification in theEuropean Unionand UKCA certification in theUnited Kingdom. The Swoop® system is commercially available in a select number of international markets.

AboutHyperfine, Inc.

Hyperfine, Inc.(Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission ofHyperfine, Inc.is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr.Jonathan Rothbergin a technology-based incubator called 4Catalyzer,Hyperfine, Inc.scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visithyperfine.io.

The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks ofHyperfine, Inc.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Actual results ofHyperfine, Inc.(the “Company”) may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s goals and commercial plans, the benefits of the Company’s products and services, and the Company’s future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the degree that theSwoop®system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s Class A common stock on the Nasdaq; the Company’s inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services and reimbursement for medical procedures conducted using the Company’s products and services; the Company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in Company’s filings with theSecurities and Exchange Commission, including those under “Risk Factors” therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241119768356/en/

Media ContactDana SchroederHealth+Commercedana@healthandcommerce.com

Investor ContactMarissa BychGilmartin Group LLCmarissa@gilmartinir.com

Source:Hyperfine, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com